Home/Insights
Insights
Ideas for the next regulatory decision.
Practical perspectives on CMC, biologics, quality risk and the digital shift in regulatory affairs — written to be useful to someone with a decision in front of them.
Browse
By topic
Why FDA places IND applications on clinical hold
FDA holds INDs for CMC deficiencies even when the biology is compelling.
Building a phase-appropriate CMC strategy for IND success
The hardest CMC question is not what data to generate but when.
Analytical comparability: the make-or-break factor in biosimilar approval
Biosimilar approval now rests mainly on analytical comparability.
CMC documentation for biologics: common deficiencies observed by health authorities
Where FDA, EMA, MHRA, PMDA and Health Canada push back most often on biologics CMC documentation, why the same gaps keep recurring, and how to build a deficiency-resistant Module 3 and Quality Overall Summary.
Structured quality knowledge: the future of biologics regulatory submissions
Document-centric CMC submissions are reaching their limits.
Managing quality risks across APIs, excipients, botanicals and food supplements
Not all raw materials carry the same risk, but every one can affect patient safety.
Raw material qualification: the first step toward patient safety and compliance
Raw material qualification is not a procurement activity — it is a cornerstone of the pharmaceutical quality system.
Editorial standard
What we will and will not publish
An insights hub is only worth having if it is useful to read. The test we apply is whether a piece helps a reader make a decision they were already facing.
Every claim carries a source. Regulatory, scientific and performance claims are identified, referenced and reviewed before publication. Where something is our opinion, we say so.
Every piece has an owner and a review date. Regulatory content goes stale. Anything we publish is scheduled for review, and retired or updated when it no longer holds.
No thin promotional content. A piece that exists only to rank for a search term is not worth your attention or our name on it.
Start a conversation
Working on something one of these touches?
The published version is often less useful than the conversation. If a topic here is live for you, tell us where you have got to.